The 3 best performing ASX shares of the week of 5 December 2022
Marc Kennis, December 12, 2022
The 3 best performing ASX shares in the week of 5 December 2022
The 3 best performing ASX shares of the week starting 5 December 2022 were Tombador Iron (ASX:TI1), up 38.1%, Macarthur Minerals (ASX:MIO), up 25%, and Cardiex (ASX:CDX), up 22.2%.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
1. Tombador Iron (ASX:TI1)
Industry: Resources
Our top 3 best performing ASX shares kicks off with Tombador Iron (ASX:TI1), which owns 100% of the fully permitted Tombador Iron Ore mine located in Bahia State Brazil. Tombador commenced production of premium-grade lump and fines hematite iron ore in May 2021 from a low-capex open-pit mining operation.
Market Cap: $62m
12 month high / low: $0.019 – $0.055
2. Macarthur Minerals (ASX:MIO)
Industry: Resources
Macarthur Minerals (ASX:MIO) is an iron ore development, gold and lithium exploration company that is focused on bringing to production its 100% owned Western Australia iron ore projects.
Market Cap: $33m
12 month high / low: $0.125 – $0.64
3. Cardiex (ASX:CDX)
Industry: Healthcare
Cardiex Limited (ASX:CDX) rounds out our top 3 best performing ASX shares this week. CDX is an ASX listed public company with operations in medical technology, wearable devices and telehealth, providing digital and device-based solutions for large-scale population health disorders with significant market scale. Its current focus is cardiovascular disease (CVD) and heart health.
Market Cap: $49m
12 month high / low: $0.25 – $0.72
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years
If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something…
Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017
Cann Group (ASX:CAN) is the first company in Australia that was issued a medicinal cannabis license, granted by the Australian…
CET1 ratio: If you invest in ASX bank stocks, here’s why it is an important metric to know
In this article we look at the Common Equity Tier 1 (CET1) ratio – what it is and why it…